ARS Pharmaceuticals, Inc.

Contributing Author

Recent Articles by ARS Pharmaceuticals, Inc.

Jun-04	Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies SPRY GlobeNewswire
May-15	ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update SPRY -6.49% GlobeNewswire
May-13	ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President SPRY -7.18% GlobeNewswire
May-07	ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results SPRY GlobeNewswire
Apr-15	neffy (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) SPRY GlobeNewswire
Mar-27	ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy 1 mg (epinephrine nasal spray) Label SPRY -5.72% GlobeNewswire
Mar-09	ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) Commercialization SPRY GlobeNewswire
Feb-23	ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences SPRY GlobeNewswire
Feb-10	ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting SPRY GlobeNewswire
Feb-02	EURneffy 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg SPRY GlobeNewswire
Jan-21	California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use SPRY GlobeNewswire
Dec-29	neffy (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) SPRY GlobeNewswire
Nov-26	ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference SPRY GlobeNewswire
Nov-10	ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy (epinephrine nasal spray) SPRY GlobeNewswire
Nov-04	ARS Pharma Launches Get neffy on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray) SPRY GlobeNewswire
Nov-03	UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting SPRY GlobeNewswire
Nov-03	ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results SPRY GlobeNewswire
Nov-03	ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting SPRY GlobeNewswire
Oct-08	ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy (epinephrine nasal spray) SPRY +7.55% GlobeNewswire
Sep-29	ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy SPRY GlobeNewswire
Sep-19	neffy (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) SPRY GlobeNewswire
Sep-08	Real-World Evidence Supports Clinical Effectiveness of neffy (epinephrine nasal spray) in Patients Experiencing Anaphylaxis SPRY +6.26% GlobeNewswire
Aug-28	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences SPRY GlobeNewswire
Aug-13	ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy (epinephrine nasal spray) SPRY -5.04% GlobeNewswire
Aug-04	ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results SPRY GlobeNewswire
Jul-18	EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) SPRY GlobeNewswire
May-27	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences SPRY GlobeNewswire
May-14	ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy (epinephrine nasal spray) SPRY -9.36% GlobeNewswire
May-07	ARS Pharmaceuticals' neffy (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms SPRY GlobeNewswire
May-05	ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results SPRY GlobeNewswire
May-02	ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abello A/S to Expand Reach of neffy (epinephrine nasal spray) to Additional U.S. Pediatricians SPRY GlobeNewswire

ARS Pharmaceuticals, Inc.

Recent Articles by ARS Pharmaceuticals, Inc.

Upgrade your Finviz experience